Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Evans-Axelsson

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 4, 2018
Preserving Preclinical PET Quality During Intratherapeutic Imaging in Radionuclide Therapy with Rose Metal Shielding Reducing Photon FluxEmma Mellhammar, Magnus Dahlbom, Susan Evans-Axelsson, et al.
Cancer Immunology, Immunotherapy : CII|March 31, 2021
Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancerKristina Witt, Susan Evans-Axelsson, Andreas Lundqvist, et al.
Seminars in Nuclear Medicine|February 22, 2016
Radioimmunotherapy for Prostate Cancer--Current Status and Future PossibilitiesSusan Evans-Axelsson, Oskar Vilhelmsson Timmermand, Anders Bjartell, et al.
European Urology|July 7, 2015
The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate CancerGiacomo Canesin, Susan Evans-Axelsson, Rebecka Hellsten, et al.
Journal of Medicinal Chemistry|April 26, 2016
Preclinical Characterization of 3β-(N-Acetyl l-cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate CancerZilma Escobar, Anders Bjartell, Giacomo Canesin, et al.
Plos One|September 9, 2017
Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse modelGiacomo Canesin, Susan Evans-Axelsson, Rebecka Hellsten, et al.
American Journal of Nuclear Medicine and Molecular Imaging|April 23, 2014
Multi-radionuclide digital autoradiography of the intra-aortic atherosclerotic plaques using a monoclonal antibody targeting oxidized low-density lipoproteinAnders Orbom, Bo Jansson, Alexandru Schiopu, et al.
Nuklearmedizin. Nuclear Medicine|March 18, 2025
Intratumoral distribution and pharmacokinetics of the radiolabeled ICAM-1 targeting monoclonal antibody R6.5 in a prostate cancer mouse modelAnders Örbom, Susan Evans-Axelsson, Bo Jansson, et al.
British Journal of Pharmacology|February 13, 2025
An optimised Bcl-3 inhibitor for melanoma treatmentKarunakar Saamarthy, Renée Daams, Wondossen Sime, et al.
EJNMMI Research|June 28, 2015
Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6Oskar Vilhelmsson Timmermand, David Ulmert, Susan Evans-Axelsson, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 4, 2018
Preserving Preclinical PET Quality During Intratherapeutic Imaging in Radionuclide Therapy with Rose Metal Shielding Reducing Photon FluxEmma Mellhammar, Magnus Dahlbom, Susan Evans-Axelsson, et al.
Cancer Immunology, Immunotherapy : CII|March 31, 2021
Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancerKristina Witt, Susan Evans-Axelsson, Andreas Lundqvist, et al.
Seminars in Nuclear Medicine|February 22, 2016
Radioimmunotherapy for Prostate Cancer--Current Status and Future PossibilitiesSusan Evans-Axelsson, Oskar Vilhelmsson Timmermand, Anders Bjartell, et al.
European Urology|July 7, 2015
The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate CancerGiacomo Canesin, Susan Evans-Axelsson, Rebecka Hellsten, et al.
Journal of Medicinal Chemistry|April 26, 2016
Preclinical Characterization of 3β-(N-Acetyl l-cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate CancerZilma Escobar, Anders Bjartell, Giacomo Canesin, et al.
Plos One|September 9, 2017
Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse modelGiacomo Canesin, Susan Evans-Axelsson, Rebecka Hellsten, et al.
American Journal of Nuclear Medicine and Molecular Imaging|April 23, 2014
Multi-radionuclide digital autoradiography of the intra-aortic atherosclerotic plaques using a monoclonal antibody targeting oxidized low-density lipoproteinAnders Orbom, Bo Jansson, Alexandru Schiopu, et al.
Nuklearmedizin. Nuclear Medicine|March 18, 2025
Intratumoral distribution and pharmacokinetics of the radiolabeled ICAM-1 targeting monoclonal antibody R6.5 in a prostate cancer mouse modelAnders Örbom, Susan Evans-Axelsson, Bo Jansson, et al.
British Journal of Pharmacology|February 13, 2025
An optimised Bcl-3 inhibitor for melanoma treatmentKarunakar Saamarthy, Renée Daams, Wondossen Sime, et al.
EJNMMI Research|June 28, 2015
Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6Oskar Vilhelmsson Timmermand, David Ulmert, Susan Evans-Axelsson, et al.
Pageof 4